1. DOP17 In high-risk Crohn's Disease patients, anastomosis configuration types have similar rates of endoscopic recurrence. (27th May 2021) Authors: Bachour, S; Shah, R; Lyu, R; Rieder, F; Cohen, B; Qazi, T; Lashner, B; Lipman, J; Regueiro, M; Lightner, A; Holubar, S; Click, B Journal: Journal of Crohn's and colitis Issue: Volume 15(2021)Supplement 1 Page Start: S055 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. DOP38 Upadacitinib Therapy Reduces Crohn's Disease Symptoms Within the First Week of Induction Therapy. (30th January 2023) Authors: Colombel, J F; Hisamatsu, T; Bresso, F; Thin, L; Parra, R; Ford, S; Remple, V; Lacerda, A P; Hecht, P; Mallick, M; Garrison, A; Regueiro, M Journal: Journal of Crohn's and colitis Issue: Volume 17(2023)Supplement 1 Page Start: i102 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. DOP39 Endoscopic, histologic, and combined outcomes with reinitiation of ozanimod after temporary discontinuation: 2-year interim analysis of the True North open-label extension study. (30th January 2023) Authors: Vermeire, S; Dignass, A; Colombel, J F; Jain, A; Canavan, J B; Wu, H; Lawlor, G; Osterman, M T; Rubin, D T; Regueiro, M Journal: Journal of Crohn's and colitis Issue: Volume 17(2023)Supplement 1 Page Start: i103 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. DOP43 Extended induction in the True North OLE study: ozanimod efficacy in biologic-naive and biologic-experienced patients. (30th January 2023) Authors: Dignass, A; Regueiro, M; Colombel, J F; Jain, A; Canavan, J B; Wu, H; Lawlor, G; Osterman, M T; Vermeire, S; Rubin, D T Journal: Journal of Crohn's and colitis Issue: Volume 17(2023)Supplement 1 Page Start: i110 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. DOP43 Rapidity of ozanimod-induced symptomatic response and remission in patients with moderately to severely active Ulcerative Colitis: Results from the induction period of True North. (21st January 2022) Authors: Siegmund, B; Axelrad, J; Pondel, M; Osterman, M T; Ahmad, H A; Memaj, A; Regueiro, M; Armuzzi, A; Afzali, A Journal: Journal of Crohn's and colitis Issue: Volume 16(2022)Supplement 1 Page Start: i092 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. DOP45 Long-term cardiac safety of ozanimod in phase 3 clinical program of Ulcerative Colitis and relapsing multiple sclerosis. (21st January 2022) Authors: Armuzzi, A; Cross, R K; Lichtenstein, G; Calkwood, J; Pai, A; Pondel, M; Ahmad, H A; Charles, L; Elegbe, A; Petersen, A; Sheffield, J K; Javed, A; Hou, J; Regueiro, M; Wolf, D C; Long, M Journal: Journal of Crohn's and colitis Issue: Volume 16(2022)Supplement 1 Page Start: i094 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. P111 Cross-sectional imaging is highly sensitive in detecting endoscopic post-operative recurrence in Crohn's disease patients. (27th May 2021) Authors: Bachour, S; Shah, R S; Lyu, R; Nakamura, T; Shen, M; Li, T; Rieder, F; Cohen, B; Qazi, T; Lashner, B; Achkar, J P; Philpott, J; Lightner, A; Holubar, S; Regueiro, M; Dane, B; Baker, M; Axelrad, J; Click, B Journal: Journal of Crohn's and colitis Issue: Volume 15(2021)Supplement 1 Page Start: S203 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. P235 Patients with inflammatory ileal pouch anal anastomosis (IPAA) disorders are characterized by a distinct breath volatile organic compounds (VOC) metabolome profile. (30th January 2023) Authors: Qazi, T; Ottichilo, R; Grove, D; Rayan, C; Cohen, B; Bhat, S; Regueiro, M; Dweik, R; Rieder, F Journal: Journal of Crohn's and colitis Issue: Volume 17(2023)Supplement 1 Page Start: i388 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. P409 Non-invasive predictors of maintaining remission in patients with moderately to severely active Ulcerative Colitis treated with tofacitinib who dose-reduced from tofacitinib 10 mg twice daily to 5 mg twice daily: 6-month data from the double-blind, randomised RIVETING study. (27th May 2021) Authors: D'Haens, G R; Dubinsky, M C; Regueiro, M; Santana, G O; Torres, J; Kulisek, N; Gardiner, S; Mundayat, R; Paulissen, J; Lawendy, N; Su, C; Modesto, I; Sandborn, W J Journal: Journal of Crohn's and colitis Issue: Volume 15(2021)Supplement 1 Page Start: S416 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. P420 Safety & feasibility of targeted mesenteric approaches to ileocolic resection and anastomosis in Crohn's Disease. (30th January 2023) Authors: Holubar, S; Cohen, B; Uchino, T; Lincango, E; Prien, C; Joseph, A; Achkar, J P; Gunter, R; Lashner, B; DeLaney, C; Ban, K; Bolshinsky, V; Lipman, J; Liska, D; Philpott, J; Naseer, M; Kanters, A; Braga-Neto, M; Rieder, F; Somovilla, J Journal: Journal of Crohn's and colitis Issue: Volume 17(2023)Supplement 1 Page Start: i549 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗